Interest of Research I: Looking for anti-aging drugs

We're interested in the molecular mechanisms of aging in general. Previously, Xie joined this area by inventing the first microfluidic chip for dissecting mother and daughter cells. Before that, scientists have to manually clap the cells under a microscope. 
The microfluidic chip enable us screening drugs that's able to extend lifespan of yeast. Through this approach we will find a bunch of drugs those are potential to extend lifespan of humans.  


INTEREST OF RESEARCH II: NEW ALGORITHM for METABOLIC ANALYSIS
We're trying to intergrate the genome-scale data to the Flux Balance Analysis model by developing new mathematical algorithms. 

​INTEREST OF RESEARCH III: DRUG DISCOVERY THROUGH ARTIFICIAL INTELLIGENCE 
We're integrating systems biology, artificial intelligence to drug discoveries. We're aiming at accelerating drug discovery through deep learning. 

INTEREST OF RESEARCH IV: STRUCTURE BIOLOGY RELATED TO AGING
Epigenetics etc. 

PRICINPAL INVESTIGATOR: Zhengwei Xie

in 2020， Zhengwei moved to Peking university international cancer institute

XIE lanched a company GigaCeuticals Co., ltd. to facilitate drug development by deep learning. GigaCeuticals Co., ltd. has been funded by INNOAGNLE. 

Xie in News

DLEPS has been awarded "Ten Breakthroughs of Bioinformatics in 2021" in China. 

Nature reported the Yeast Aging chip, which is the milestone for yeast aging research. http://www.nature.com/nature/journal/v486/n7401/full/486037a.html . 

Pencilnews reported GigaCeuticals
https://m.pencilnews.cn/p/21345.html